Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs

Register of interests (PDF 135 KB)

Equality Impact Assessment (Guidance development) (PDF 144 KB)

Final draft guidance

Final appraisal document (PDF 174 KB)

Committee papers (PDF 2.37 MB)

Final scope (PDF 239 KB)

Final stakeholder list (PDF 161 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 247 KB)

Equality impact assessment (Scoping) (PDF 122 KB)

Draft scope post referral (PDF 249 KB)

Draft scope post referral (PDF 163 KB)